Matrix metalloproteinase inhibitors 1998

被引：123
作者：
Beckett, RP [1 ]
Whittaker, M [1 ]
机构：
[1] British Biotech Pharmaceut Ltd, Dept Med Chem, Oxford OX4 5LY, England
来源：
EXPERT OPINION ON THERAPEUTIC PATENTS | 1998年 / 8卷 / 03期
关键词：
arthritis; cancer; collagenase; gelatinase; matrix metalloproteinase; stromelysin; tumour necrosis factor-alpha;
D O I：
10.1517/13543776.8.3.259
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Inhibition of matrix metalloproteinases (MMPs) as an approach to treatment of diseases such as cancer, arthritis and multiple sclerosis (MS) is now an area of intense interest within the pharmaceutical industry. This review summarises developments in the design and clinical evaluation of synthetic MMP inhibitors since the subject was last covered in this journal in 1996.
引用
收藏
页码：259 / 282
页数：24
相关论文
共 85 条
  • [21] Potent carboxylate inhibitors of stromelysin containing P2' piperazic acids and P1' biaryl moeities
    Cherney, RJ
    Decicco, CP
    Nelson, DJ
    Wang, L
    Meyer, DT
    Hardman, KD
    Copeland, RA
    Arner, EC
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (13) : 1757 - 1762
  • [22] Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor
    Clements, JM
    Cossins, JA
    Wells, GMA
    Corkill, DJ
    Helfrich, K
    Wood, LM
    Pigott, R
    Stabler, G
    Ward, GA
    Gearing, AJH
    Miller, KM
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 1997, 74 (1-2) : 85 - 94
  • [23] THE INFLUENCE OF PEPTIDE STRUCTURE ON TRANSPORT ACROSS CACO-2 CELLS .2. PEPTIDE-BOND MODIFICATION WHICH RESULTS IN IMPROVED PERMEABILITY
    CONRADI, RA
    HILGERS, AR
    HO, NFH
    BURTON, PS
    [J]. PHARMACEUTICAL RESEARCH, 1992, 9 (03) : 435 - 439
  • [24] Davidson AH, 1997, CHEM IND-LONDON, P258
  • [25] DAVIES SJ, 1997, 9 RSC SCI MED CHEM S
  • [26] Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics
    Decicco, CP
    Seng, JL
    Kennedy, KE
    Covington, MB
    Welch, PK
    Arner, EC
    Magolda, RL
    Nelson, DJ
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (18) : 2331 - 2336
  • [27] DECICCO CP, 1997, SRI RAND RAT C PRINC
  • [28] Matrix metalloproteinase inhibitors: Present achievements and future prospects
    Denis, LJ
    Verweij, J
    [J]. INVESTIGATIONAL NEW DRUGS, 1997, 15 (03) : 175 - 185
  • [29] Rifamycins as inhibitors of collagenase activity: Their possible pharmacological role in collagen degradative diseases
    DiGiulio, A
    Barracchini, A
    Cellai, L
    Martuccio, C
    Amicosante, G
    Oratore, A
    Pantaleoni, G
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 144 (01) : 27 - 35
  • [30] Anti-arthritic activity of hydroxamic acid-based pseudopeptide inhibitors of matrix metalloproteinases and TNF alpha processing
    DiMartino, M
    Wolff, C
    High, W
    Stroup, G
    Hoffman, S
    Laydon, J
    Lee, JC
    Bertolini, D
    Galloway, WA
    Crimmin, MJ
    Davis, M
    Davies, S
    [J]. INFLAMMATION RESEARCH, 1997, 46 (06) : 211 - 215
123456789